E Fund Management Co. Ltd. Boosts Holdings in DexCom, Inc. (NASDAQ:DXCM)

E Fund Management Co. Ltd. increased its holdings in DexCom, Inc. (NASDAQ:DXCM) by 41.9% during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 9,825 shares of the medical device company’s stock after buying an additional 2,899 shares during the quarter. E Fund Management Co. Ltd.’s holdings in DexCom were worth $764,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds also recently made changes to their positions in DXCM. Jennison Associates LLC boosted its holdings in shares of DexCom by 1,683.2% in the third quarter. Jennison Associates LLC now owns 6,932,899 shares of the medical device company’s stock worth $464,782,000 after buying an additional 6,544,102 shares during the last quarter. Congress Asset Management Co. lifted its holdings in DexCom by 5,456.9% during the fourth quarter. Congress Asset Management Co. now owns 1,356,941 shares of the medical device company’s stock valued at $105,529,000 after purchasing an additional 1,332,522 shares in the last quarter. Fisher Funds Management LTD purchased a new position in DexCom during the fourth quarter valued at approximately $96,507,000. Westfield Capital Management Co. LP lifted its holdings in DexCom by 44.6% during the third quarter. Westfield Capital Management Co. LP now owns 2,842,057 shares of the medical device company’s stock valued at $190,532,000 after purchasing an additional 876,739 shares in the last quarter. Finally, Two Sigma Advisers LP lifted its holdings in DexCom by 182.7% during the third quarter. Two Sigma Advisers LP now owns 1,143,476 shares of the medical device company’s stock valued at $76,659,000 after purchasing an additional 739,000 shares in the last quarter. Hedge funds and other institutional investors own 97.75% of the company’s stock.

DexCom Trading Down 2.1 %

Shares of DXCM opened at $77.84 on Friday. The company’s fifty day moving average is $84.83 and its 200 day moving average is $76.96. DexCom, Inc. has a fifty-two week low of $62.34 and a fifty-two week high of $142.00. The stock has a market capitalization of $30.42 billion, a PE ratio of 54.43, a P/E/G ratio of 2.30 and a beta of 1.28. The company has a debt-to-equity ratio of 0.59, a quick ratio of 1.28 and a current ratio of 1.47.

DexCom (NASDAQ:DXCM) last posted its quarterly earnings data on Thursday, February 13th. The medical device company reported $0.45 earnings per share for the quarter, missing analysts’ consensus estimates of $0.50 by ($0.05). DexCom had a net margin of 14.29% and a return on equity of 30.14%. Sell-side analysts expect that DexCom, Inc. will post 2.03 earnings per share for the current fiscal year.

Analysts Set New Price Targets

DXCM has been the topic of several analyst reports. Canaccord Genuity Group lifted their price target on shares of DexCom from $99.00 to $103.00 and gave the company a “buy” rating in a report on Friday, February 14th. Citigroup lifted their price target on shares of DexCom from $101.00 to $104.00 and gave the company a “buy” rating in a report on Tuesday. Robert W. Baird raised shares of DexCom from a “neutral” rating to an “outperform” rating and lifted their price target for the company from $86.00 to $104.00 in a report on Thursday, January 16th. Redburn Atlantic raised shares of DexCom from a “neutral” rating to a “buy” rating and boosted their target price for the stock from $85.00 to $115.00 in a report on Monday, February 3rd. Finally, Baird R W raised shares of DexCom from a “hold” rating to a “strong-buy” rating in a report on Thursday, January 16th. Four investment analysts have rated the stock with a hold rating, thirteen have given a buy rating and two have issued a strong buy rating to the company’s stock. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $99.82.

Insider Buying and Selling at DexCom

In other DexCom news, COO Jacob Steven Leach sold 2,634 shares of the business’s stock in a transaction on Wednesday, January 29th. The shares were sold at an average price of $86.91, for a total transaction of $228,920.94. Following the transaction, the chief operating officer now owns 268,644 shares in the company, valued at $23,347,850.04. The trade was a 0.97 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, EVP Jereme M. Sylvain sold 2,090 shares of the company’s stock in a transaction dated Wednesday, January 29th. The stock was sold at an average price of $86.91, for a total transaction of $181,641.90. Following the completion of the transaction, the executive vice president now owns 83,526 shares in the company, valued at approximately $7,259,244.66. The trade was a 2.44 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 38,083 shares of company stock worth $3,309,794 over the last quarter. Insiders own 0.30% of the company’s stock.

About DexCom

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.